Introduction
============

Chronic obstructive pulmonary disease (COPD) continues to be a major cause of disability, mortality, and rising health care costs. In 2005, 210 million people were diagnosed with COPD worldwide, and 3 million died of the disease.[@b1-copd-9-469] In the United States, it is estimated that more than 12 million people are affected by the disease, and COPD has become the third leading cause of death after cardiovascular disease and malignancy.[@b2-copd-9-469] It is predicted that COPD will also become the third leading cause of death worldwide by 2030.[@b3-copd-9-469]

Current guidelines developed by Global Initiative for COPD recommend a combination of an inhaled corticosteroid (ICS) and a long-acting beta agonist (LABA) in patients with severe disease (stage III and IV) who are experiencing frequent exacerbations.[@b4-copd-9-469] Results from a large randomized trial, Toward a Revolution in COPD Health (TORCH), including over 6,000 patients with severe COPD, suggest that treatment with ICS/LABA combination therapy resulted in a reduced rate of exacerbations, improved health status, and greater lung function values relative to placebo and the other agents.[@b5-copd-9-469] A trend toward improved survival with the ICS/LABA combination therapy was not statistically significant and of questionable clinical relevance.

Currently, there are five ICS/LABA combination products available on the market: budesonide/formoterol (BUD/FM), "Symbicort" (AstraZeneca, Wilmington, DE, USA); fluticasone propionate/salmeterol (FP/SAL), "Advair", "Seretide", "Viani", "Adoair", or "Foxair" (GlaxoSmithKline, Brentford, UK); mometasone/formoterol (MF/FM), "Dulera" or "Zenhale" (Merck, White House Station, NJ, USA); beclomethasone dipropionate/formoterol (BDP/FM), "Fostair" (Chiesi Ltd, Cheadle, UK); and fluticasone furoate/vilanterol (FF/VI), "Breo" or "Relvar Ellipta" (GlaxoSmithKline).[@b6-copd-9-469]

When no clinical trials exist that directly compare all relevant treatment options, indirect comparisons can be made by comparing the relative effects of treatments against a common comparator or combining a variety of comparisons that taken together form one or more chains linking the treatments of interest (variously referred to as a mixed or multiple treatment comparison or network meta-analysis).[@b7-copd-9-469] The purpose of this study was to systematically review the efficacy of various ICS/LABA combinations in COPD from randomized controlled trials with a Bayesian network meta-analysis.

Materials and methods
=====================

Identification of trials
------------------------

We identified all relevant clinical trials that studied clinical efficacies of an ICS/LABA combination in COPD. Two authors independently searched the Ovid Medline database for studies published from 1946 to January 21, 2014 using Medical Subject Headings (MeSH) and keywords: randomized controlled trial AND pulmonary disease, chronic obstructive AND FM, SAL, or VI AND FF, FP, BUD, MF, or BDP. In addition, we searched Scopus, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and the internet, including the online trial registries of above mentioned ICS/LABA manufacturers. Bibliographies of all selected articles and review articles that included information on ICS/LABA combination therapy in COPD were also reviewed for other relevant articles. We included any randomized clinical trial, published or unpublished, evaluating COPD patients with an ICS/LABA combination. Randomized control trials had to be of at least 12 weeks duration. Control interventions included active interventions and/or placebo. Searches were limited to English language. We excluded pharmacokinetic studies, proof of concept studies, and trials with a cross-over design. Two reviewers independently screened studies by title and abstract to evaluate whether a trial met the inclusion criteria. Disagreement between reviewers was resolved by consensus. We chose moderate-to-severe and severe exacerbations as the outcome assessment criteria for the purpose of our meta-analysis. We extracted data on COPD exacerbations as moderate and severe. Moderate was defined as "worsening respiratory status which required additional medication such as oral steroids and/or antibiotics" and severe as "rapid deterioration of respiratory status which was life-threatening or required hospitalization". A subgroup analysis was planned a priori for exacerbations selecting clinical trials which did not exclude patients receiving long-term oxygen therapy (LTOT).

Statistical analysis
--------------------

The primary analyses were conducted with a Bayesian Markov chain Monte Carlo method and fitted with the Bayesian software in WinBUGS version 1.4.3 (Medical Research Council Biostatistics Unit, Cambridge, UK).[@b8-copd-9-469] Bayesian meta-analyses involve data, a likelihood distribution, a model with parameters, and prior distributions. The technique estimates the relative efficacy between treatments that have not been directly compared and provides the most flexible approach to indirect comparison modeling. It has become a very popular tool when multiple treatments exist for a given condition. For the analyses in WinBUGS, every sample consisted of 100,000 iterations with an initial burn-in period of 10,000 iterations.[@b9-copd-9-469] We used a Poisson likelihood and a log link. Each pair of treatments was compared by estimating a hazard ratio (HR) of the outcome. The Poisson model is useful for repeated event data such as number of exacerbations, where each individual may have more than one event.[@b10-copd-9-469]

To assess the impact of ICS/LABA combinations on moderate-to-severe and severe exacerbations, data was extracted in the form of rates and given as the number of events per person-years observed. When the number of events was not available in a given study, we substituted the number of subjects who experienced an exacerbation. We assumed that each of the log HRs had been sampled from a normal distribution and that the hazard was constant in each arm over the follow-up period. We gave vague priors for all trial baselines, treatment effects, and between-trial variances.

The autocorrelation plots showed that throughout the iterative process, the autocorrelation was satisfactorily reduced to a nominal amount and the Brooks--Gelman--Rubin plots showed that the model had converged satisfactorily.[@b9-copd-9-469] We assessed the fit of our model using the deviance information criterion (DIC), a measure of model fit that penalizes model complexity. This criterion advocates selecting the model with the lowest DIC value among a series of competing models for the same data, as this model is believed to provide the best fit to the data.[@b11-copd-9-469] All results for the network meta-analysis were reported as posterior means with corresponding 95% credibility intervals (CrIs). CrIs are the Bayesian equivalent of classical confidence intervals.

Results
=======

Study selection
---------------

The electronic database searches identified 219 citations. One hundred seventy four studies were excluded on abstract review. The remaining 45 studies were reviewed for further details. An additional 27 studies were excluded for various reasons, as shown in [Figure 1](#f1-copd-9-469){ref-type="fig"}. One online first study and two unpublished studies (SFCT01 and SUMIRE) were found on the internet and the manufacture's websites.[@b12-copd-9-469]--[@b14-copd-9-469] We included 21 studies comparing five different ICS/LABA combinations for moderate-to-severe exacerbations and 13 studies for severe exacerbations including a total of 26,868 and 19,368 patients, respectively.[@b5-copd-9-469],[@b12-copd-9-469]--[@b31-copd-9-469] The study and patient characteristics are presented in [Table 1](#t1-copd-9-469){ref-type="table"}. The mean ages (range: 60--66 years), proportion of male patients (range: 54%--95%), and the mean baseline percentage predicted forced expiratory volume in 1 second (FEV~1~; range: 33%--47%) were comparable across the studies. The definitions of COPD exacerbations were similar across the included studies ([Table S1](#SD1-copd-9-469){ref-type="supplementary-material"}). The network of treatments is displayed in [Figure 2](#f2-copd-9-469){ref-type="fig"}. The treatments formed a closed network, which was amenable to multiple treatment comparison analyses.

Methodological quality of included studies
------------------------------------------

Generally, the risk of bias in the included studies appeared moderate to low. Allocation concealment was appropriate in ten studies and unclear in eleven studies. Eleven out of 21 studies presented intention-to-treat analyses. All studies were double blinded ([Table 1](#t1-copd-9-469){ref-type="table"}). In the opinion of the authors, there were no studies that clearly should have been excluded from the analysis because of differences in baseline characteristics or poor quality.

Comparison of ICS/LABA combinations on moderate-to-severe exacerbations
-----------------------------------------------------------------------

When the efficacy of various strengths of each ICS/LABA combination was assessed individually, all but BUD/FM 400/12 (400 μg/12 μg) and BDP/FM 200/12 (200 μg/12 μg) reduced moderate-to-severe exacerbations as compared with placebo. When the overall efficacy of each ICS/LABA combination was assessed (all strengths of each combination combined), all but BDP/FM reduced moderate-to-severe exacerbations ([Figure 3](#f3-copd-9-469){ref-type="fig"}). The BDP/FM combination had the lowest sample size of 718 as compared with other combinations (FP/SAL, n=12,354; BUD/FM, n=7,667; FF/VI, n=3,878; MF/FM, n=2,251). All combination therapy except FF/VI 50/25, FP/SAL 250/50, BUD/FM 400/12, and BDP/FM 200/12 reduced moderate-to-severe exacerbations as compared with LABA alone. BDP/FM was the only combination which did not reduce moderate-to-severe exacerbations when the overall efficacy of each ICS/LABA combination was compared with that of LABA alone ([Figure 4](#f4-copd-9-469){ref-type="fig"}). Medium-dose ICS/LABA combinations were as effective as high-dose ICS/LABA combinations in reducing moderate-to-severe exacerbations when directly compared. Random models gave lower DIC scores than fixed models. Therefore, random models were used for the above analyses.

Comparison of ICS/LABA combinations on severe exacerbations
-----------------------------------------------------------

None of the ICS/LABA combination therapy reduced severe exacerbations as compared with placebo or LABA. ([Figures 5](#f5-copd-9-469){ref-type="fig"} and [6](#f6-copd-9-469){ref-type="fig"}). The results were unchanged when the overall efficacy of each combination therapy was assessed with all strengths of each combination combined. Although most of the combination therapy showed a trend toward decreased incidence of severe exacerbations, the difference did not reach statistical significance. The BUD/FM 320/9 combination, as compared with placebo, was the closest to being statistically significant with an HR of 0.68 (95% CrI 0.49 to 1.00). Random models were used for the analyses above because of their lower DIC scores as compared with those of fixed models. The sample size for FP/SAL, BUD/FM, FF/VI, MF/FM, and BDP/FM was 7,938, 4,583, 3,878, 2,251, and 718 respectively.

A subgroup analysis was performed for severe exacerbations, selecting clinical trials which did not exclude patients receiving LTOT. BUD/FM did not reduce severe exacerbations as compared with LABA alone, even in such a population. The results were unchanged when BUD/FM 160/9 and 320/9 formulations were assessed individually. A subgroup analysis for BUD/FM versus placebo or other ICS/LABA combinations could not be done due to a lack of data.

Discussion
==========

Our analysis demonstrated that most of the ICS/LABA combinations reduced moderate-to-severe exacerbations as compared with placebo and LABA, but none of them reduced severe exacerbations. This is the first study which examined the class effects of ICS/LABA combinations in patients with COPD. Medium-dose ICS/LABA combinations were as effective as high-dose ICS/LABA combinations in reducing moderate-to-severe exacerbations. A few ICS/LABA combinations, namely BUD/FM 400/12 and BDP/FM 200/12, failed to reduce moderate-to-severe exacerbations. However, the samples size of those formulations was not as large as other formulations.

In the TORCH study, FP/SAL 500/25 significantly reduced severe exacerbations when compared with placebo but not with LABA.[@b5-copd-9-469] Four studies, three for FP/SAL 500/25 (including TORCH) and one for 250/50, were included in our analysis for FP/SAL ([Table 1](#t1-copd-9-469){ref-type="table"}). One study was unpublished. In our analysis, FP/SAL did not reduce severe exacerbations as compared with placebo or LABA. The results were unchanged when two strengths of FP/SAL were analyzed individually or combined, and excluding the unpublished study also did not affect the results. It is possible that the TORCH study may have overestimated the impact of FP/SAL on severe exacerbations. The number of patients included in our analysis for FP/SAL was 7,938 as compared with 6,112 for the TORCH study. Bayesian analyses generally give wider 95% CrIs than the frequentist method because the Bayesian approach incorporates all sources of uncertainty into the model. On the other hand, it is possible that the pooled analysis with heterogeneous data may have diluted the robust TORCH data.

Nannini et al pooled two studies[@b17-copd-9-469],[@b19-copd-9-469] using the rate ratio and mean difference and concluded that BUD/FM reduced severe exacerbations compared with placebo.[@b32-copd-9-469] We included four studies for BUD/FM, including one unpublished, to evaluate its impact on severe exacerbations. We used the number of events per person-years observed and analyzed data using the Poisson model, which is useful for repeated event data where each individual may have more than one event.[@b10-copd-9-469] The difference in methodology and number of included studies could explain the difference in results between Nannini's study and ours. Excluding the unpublished studies[@b12-copd-9-469],[@b13-copd-9-469] did not affect the results of our analysis.

Our study has the following limitations. First, it was assumed that there were no significant differences in efficacies among various formulations of LABAs and ICSs when they were used alone. In our pooled analysis, eight studies did not have a placebo arm. We tried to include as many studies as possible to be most comprehensive, utilizing direct and indirect comparisons with a large network. To assure the robustness of our analysis, we compared the efficacy of ICS/LABA combinations anchored on placebo only, and the results were unchanged. There were no studies directly comparing BDP/FM with placebo ([Figure 2](#f2-copd-9-469){ref-type="fig"}). Therefore, BDP/FM could not be included in such analysis.

Second, we used the number of exacerbations per person-years observed to assess the exacerbation rates. The efficacy of MF/FM combination was derived from one study which reported the number of subjects instead of exacerbation events for moderate-to-severe exacerbations.[@b28-copd-9-469] We used the number of subjects in place of exacerbation events for this arm because excluding this study would have precluded the inclusion of the MF/FM arm. We assumed the point estimate of efficacy would be quite similar when using the number of subjects instead of events because we picked the HR instead of mean difference as the outcome assessment parameter. In addition, excluding the MF/FM arm did not affect the results of other combination therapies.

Third, we did not include other outcomes such as mortality or quality of life. No randomized controlled trials of ICS/LABA combination have shown a significant mortality benefit. We felt it would be just hypothesis-generating, even if we found a significant mortality benefit with the current analysis. A previous meta-analysis failed to show mortality benefit with ICS/LABA combinations.[@b32-copd-9-469] We also believed preventing exacerbations would improve quality of life, which was already demonstrated in the previous meta-analysis with ICS/LABA combinations as compared with placebo.[@b32-copd-9-469]

Fourth, the clinical heterogeneity of the trials included in our analysis might have affected the estimates of treatment effects. For example, only seven out of 23 studies included patients receiving LTOT for 12 hours or longer ([Table 1](#t1-copd-9-469){ref-type="table"}). The subgroup analysis limited to studies which included patients receiving LTOT failed to show that ICS/LABA combination therapy was superior to LABA alone in reducing severe exacerbations. The subgroup analysis was possible only for BUD/FM versus LABA alone because of a lack of data. Further studies are needed to examine the impact of an ICS/LABA combination on severe exacerbations in the most severely affected patients with COPD receiving LTOT.

In conclusion, our analysis demonstrated that ICS/LABA combinations had a class effect with regard to the prevention of COPD exacerbations. No particular formulation is better than the other. Moderate-dose ICS/LABA combinations were as effective as high-dose ICS/LABA combinations. None of the ICS/LABA combinations reduced severe exacerbations contrary to the results of the TORCH study. ICS/LABA combination therapy may not be as efficacious as the TORCH study suggested in reducing severe exacerbations.

Supplementary material
======================

###### 

Definitions of COPD exacerbations in the included trials

  Study, year                                 Moderate                                                                                                                                                                                          Severe
  ------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------
  Mahler et al, 2002[@b15-copd-9-469]         Requiring either oral antibiotics and/or corticosteroids                                                                                                                                          Requiring in-hospital admission for a COPD exacerbation
  Calverley et al, 2003[@b16-copd-9-469]      Worsening of COPD symptoms that required treatment with antibiotics, oral corticosteroids, or both                                                                                                Requiring hospitalization
  Calverley et al, 2003[@b17-copd-9-469]      Requiring medical intervention (oral antibiotics and/or corticosteroids)                                                                                                                          Requiring hospitalization
  Hanania et al, 2003[@b18-copd-9-469]        Requiring treatment with antibiotics and/or corticosteroids                                                                                                                                       Requiring hospitalization
  Szafranski et al, 2003[@b19-copd-9-469]     Requiring antibiotics and/or oral corticosteroids                                                                                                                                                 Requiring hospitalization
  SFCT01 study, 2005[@b12-copd-9-469]         Requiring treatment with antibiotics and/or oral corticosteroids                                                                                                                                  Requiring emergency hospital treatment and hospitalization
  Calverley et al, 2007[@b5-copd-9-469]       Requiring treatment with antibiotic agents and/or systemic corticosteroids                                                                                                                        Requiring hospitalization
  Kardos et al, 2007[@b20-copd-9-469]         Requiring both a change of respiratory medication (increased dose of prescribed or addition of new drugs, ie, antibiotics, mucolytics, systemic steroids, theophylline), and medical assistance   Deterioration in COPD resulting in hospitalization or emergency room treatment
  Zheng et al, 2007[@b21-copd-9-469]          Worsening of symptoms that required treatment with antibiotics or oral corticosteroids                                                                                                            Worsening of symptoms that required hospitalization
  Ferguson et al, 2008[@b22-copd-9-469]       Requiring treatment with oral corticosteroids or antibiotics                                                                                                                                      Requiring hospitalization
  Tashkin et al, 2008[@b23-copd-9-469]        Requiring treatment with oral corticosteroids                                                                                                                                                     Requiring hospitalization
  Anzueto et al, 2009[@b24-copd-9-469]        Requiring antibiotics and/or oral corticosteroids                                                                                                                                                 Requiring hospitalization
  Rennard et al, 2009[@b25-copd-9-469]        Requiring an oral corticosteroid                                                                                                                                                                  Requiring hospitalization
  Calverley et al, 2010[@b26-copd-9-469]      Need for treatment with oral corticosteroids and/or antibiotics                                                                                                                                   Need to visit or be admitted to a hospital
  SUMIRE study, 2011[@b13-copd-9-469]         Requiring treatment with a course of systemic steroid                                                                                                                                             Requiring hospitalization
  Sharafkhaneh et al, 2012[@b27-copd-9-469]   Requiring antibiotics and/or oral corticosteroids                                                                                                                                                 Requiring hospitalization
  Tashkin et al, 2012[@b28-copd-9-469]        Requiring antibiotic and/or oral steroid treatment                                                                                                                                                Requiring emergency treatment or hospitalization
  Zhong et al, 2012[@b29-copd-9-469]          Requiring oral/intravenous corticosteroids and/or antibiotics                                                                                                                                     Requiring emergency room treatment or hospitalization
  Dransfield et al, 2013[@b14-copd-9-469]     Necessitating treatment with oral corticosteroids or antibiotics or both                                                                                                                          Necessitating hospital admission
  Kerwin et al, 2013[@b31-copd-9-469]         Requiring systemic corticosteroids and/or antibiotics                                                                                                                                             Requiring hospitalization
  Martinez et al, 2013[@b30-copd-9-469]       Requiring systemic corticosteroids and/or antibiotics                                                                                                                                             Requiring hospitalization

**Abbreviation:** COPD, chronic obstructive pulmonary disease.
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![Flow of study selection.](copd-9-469Fig1){#f1-copd-9-469}

![Diagram displaying the network of eight arms involved in the Bayesian analyses.\
**Notes:** The links between nodes are used to indicate a direct comparison between pairs of treatments. The numbers shown along the link lines indicate the number of trials comparing pairs of treatments head-to-head.\
**Abbreviations:** BDP, beclomethasone dipropionate; BUD, budesonide; FF, fluticasone furoate; FM, formoterol; FP, fluticasone propionate; ICS, inhaled corticosteroids; LABA, long-acting beta agonists; MF, mometasone furoate; PLB, placebo; SAL, salmeterol; VI, vilanterol.](copd-9-469Fig2){#f2-copd-9-469}

![Pooled effect estimate on moderate-to-severe exacerbations for all combined inhalers versus placebo.\
**Abbreviations:** BDP, beclomethasone dipropionate; BUD, budesonide; FF, fluticasone furoate; FM, formoterol; FP, fluticasone propionate; MF, mometasone furoate; SAL, salmeterol; VI, vilanterol.](copd-9-469Fig3){#f3-copd-9-469}

![Pooled effect estimate on moderate-to-severe exacerbations for all combined inhalers versus long acting beta-agonist.\
**Abbreviations:** BDP, beclomethasone dipropionate; BUD, budesonide; FF, fluticasone furoate; FM, formoterol; FP, fluticasone propionate; MF, mometasone furoate; SAL, salmeterol; VI, vilanterol.](copd-9-469Fig4){#f4-copd-9-469}

![Pooled effect estimate on severe exacerbations for all combined inhalers versus placebo.\
**Abbreviations:** BDP, beclomethasone dipropionate; BUD, budesonide; FF, fluticasone furoate; FM, formoterol; FP, fluticasone propionate; MF, mometasone furoate; SAL, salmeterol; VI, vilanterol.](copd-9-469Fig5){#f5-copd-9-469}

![Pooled effect estimate on severe exacerbations for all combined inhalers versus long acting beta-agonist.\
**Abbreviations:** BDP, beclomethasone dipropionate; BUD, budesonide; FF, fluticasone furoate; FM, formoterol; FP, fluticasone propionate; MF, mometasone furoate; SAL, salmeterol; VI, vilanterol.](copd-9-469Fig6){#f6-copd-9-469}

###### 

Study characteristics of included trials that provide data on the total number of exacerbations and/or the mean annual rate of exacerbations

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study, year                                 Number of patients   Duration of treatment (weeks)   Treatment comparisons          Baseline characteristics   Reported severity of exacerbations   Quality assessment                                                                                                             
  ------------------------------------------- -------------------- ------------------------------- ------------------------------ -------------------------- ------------------------------------ ---------------------------------------------- ----------------------------------------------- ----- ----- --------- --------- -----
  Mahler et al, 2002[@b15-copd-9-469]         674                  24                              FP/SAL (500/50 μg bid)\        63                         66                                   41                                             Yes                                             Yes   NR    Unclear   Unclear   Yes
                                                                                                   SAL (50 μg bid)\                                                                                                                                                                                                              
                                                                                                   FP (500 μg bid)\                                                                                                                                                                                                              
                                                                                                   PLB bid                                                                                                                                                                                                                       

  Calverley et al, 2003[@b16-copd-9-469]      1,465                52                              FP/SAL (500/50 μg bid)\        63                         73                                   45                                             Yes                                             Yes   NR    Yes       Yes       Yes
                                                                                                   SAL (50 μg bid)\                                                                                                                                                                                                              
                                                                                                   FP (500 μg bid)\                                                                                                                                                                                                              
                                                                                                   PLB bid                                                                                                                                                                                                                       

  Calverley et al, 2003[@b17-copd-9-469]      1,022                52                              BUD/FM (320/9 μg bid)\         64                         76                                   36                                             Yes                                             Yes   Yes   Unclear   Unclear   Yes
                                                                                                   FM (9 μg bid)\                                                                                                                                                                                                                
                                                                                                   BUD (400 μg bid)\                                                                                                                                                                                                             
                                                                                                   PLB bid                                                                                                                                                                                                                       

  Hanania et al, 2003[@b18-copd-9-469]        723                  24                              FP/SAL (250/50 μg bid)\        64                         63                                   42                                             Yes                                             Yes   NR    Unclear   Unclear   Yes
                                                                                                   SAL (50 μg bid)\                                                                                                                                                                                                              
                                                                                                   FP (250 μg bid)\                                                                                                                                                                                                              
                                                                                                   PLB bid                                                                                                                                                                                                                       

  Szafranski et al, 2003[@b19-copd-9-469]     812                  52                              BUD/FM (320/9 μg bid)\         64                         79                                   36                                             Yes                                             Yes   NR    Yes       Yes       Yes
                                                                                                   FM (9 μg bid)\                                                                                                                                                                                                                
                                                                                                   BUD (400 μg bid)\                                                                                                                                                                                                             
                                                                                                   PLB bid                                                                                                                                                                                                                       

  SFCT0I study, 2005[@b12-copd-9-469]         387                  52                              FP/SAL (250/50 μg bid)\        64                         80                                   NR                                             Yes                                             Yes   Yes   Unclear   Unclear   Yes
                                                                                                   SAL (50 μg bid)\                                                                                                                                                                                                              
                                                                                                   FP (250 μg bid)\                                                                                                                                                                                                              
                                                                                                   PLB bid                                                                                                                                                                                                                       

  Calverley et al, 2007[@b5-copd-9-469]       6,112                156                             FP/SAL (500/50 μg bid)\        65                         76                                   44                                             Yes                                             Yes   Yes   Yes       Yes       Yes
                                                                                                   SAL (50 μg bid)\                                                                                                                                                                                                              
                                                                                                   FP (500 μg bid)\                                                                                                                                                                                                              
                                                                                                   PLB bid                                                                                                                                                                                                                       

  Kardos et al, 2007[@b20-copd-9-469]         994                  44                              FP/SAL (500/50 μg bid)\        64                         76                                   40                                             Yes                                             Yes   Yes   Yes       Yes       Yes
                                                                                                   SAL (50 μg bid)                                                                                                                                                                                                               

  Zheng et al, 2007[@b21-copd-9-469]          445                  24                              FP/SAL (500/50 μg bid)\        66                         89                                   47                                             Yes[†](#tfn2-copd-9-469){ref-type="table-fn"}   Yes   Yes   Unclear   Unclear   Yes
                                                                                                   PLB bid                                                                                                                                                                                                                       

  Ferguson et al, 2008[@b22-copd-9-469]       776                  52                              FP/SAL (250/50 μg bid)\        65                         55                                   33                                             No                                              Yes   NR    Yes       Unclear   Yes
                                                                                                   SAL (50 μg bid)                                                                                                                                                                                                               

  Tashkin et al, 2008[@b23-copd-9-469]        1,417                24                              BUD/FM (160--320/9 μg bid)\    63                         69                                   40                                             No                                              Yes   Yes   Unclear   Yes       Yes
                                                                                                   FM (9 μg bid)\                                                                                                                                                                                                                
                                                                                                   BUD (320 μg bid)\                                                                                                                                                                                                             
                                                                                                   PLB bid                                                                                                                                                                                                                       

  Anzueto et al, 2009[@b24-copd-9-469]        778                  52                              FP/SAL (250/50 μg bid)\        65                         54                                   34                                             No                                              Yes   NR    Unclear   Unclear   Yes
                                                                                                   SAL (50 μg bid)                                                                                                                                                                                                               

  Rennard et al, 2009[@b25-copd-9-469]        1,964                52                              BUD/FM (160--320/9 μg bid)\    63                         64                                   40                                             No                                              Yes   NR    Unclear   Yes       Yes
                                                                                                   FM (9 μg bid)\                                                                                                                                                                                                                
                                                                                                   PLB bid                                                                                                                                                                                                                       

  Calverley et al, 2010[@b26-copd-9-469]      718                  48                              BDP/FM (400--800/24 μg bid)\   64                         81                                   42                                             Yes                                             Yes   Yes   Yes       Yes       Yes
                                                                                                   FM 24 bid                                                                                                                                                                                                                     

  SUMIRE study, 2011[@b13-copd-9-469]         1,293                12                              BUD/FM (320/9 μg bid)\         65                         89                                   36                                             No                                              Yes   Yes   Unclear   Unclear   Yes
                                                                                                   FM (9 μg bid)                                                                                                                                                                                                                 

  Sharafkhaneh et al, 2012[@b27-copd-9-469]   851                  52                              BUD/FM (160--320/9 μg bid)\    63                         62                                   38[¶](#tfn1-copd-9-469){ref-type="table-fn"}   No                                              Yes   Yes   Yes       Unclear   Yes
                                                                                                   FM (9 μg bid)                                                                                                                                                                                                                 

  Tashkin et al, 2012[@b28-copd-9-469]        2,251                26                              MF/FM (200--400/10 μg bid)\    60                         76                                   39                                             Yes                                             Yes   Yes   Yes       Unclear   Yes
                                                                                                   MF (400 μg bid)\                                                                                                                                                                                                              
                                                                                                   FM (10 μg bid)\                                                                                                                                                                                                               
                                                                                                   PLB bid                                                                                                                                                                                                                       

  Zhong et al, 2012[@b29-copd-9-469]          308                  24                              BUD/FM (160/4.5 μg bid)\       65                         95                                   33                                             No                                              Yes   NR    Unclear   Yes       Yes
                                                                                                   BUD (200 μg bid)                                                                                                                                                                                                              

  Dransfield et al, 2013[@b14-copd-9-469]     1,624                52                              FF/VI (100/25 μg qd)\          64                         58                                   45                                             Yes[†](#tfn2-copd-9-469){ref-type="table-fn"}   Yes   Yes   Yes       Yes       Yes
                                                                                                   VI (25 μg qd)                                                                                                                                                                                                                 

  Kerwin et al, 2013[@b31-copd-9-469]         1,030                24                              FF/VI (100--200/25 μg qd)\     63                         67                                   43                                             Yes                                             Yes   Yes   Yes       Yes       Yes
                                                                                                   FF (100)\                                                                                                                                                                                                                     
                                                                                                   VI (25 μg qd)\                                                                                                                                                                                                                
                                                                                                   PLB qd                                                                                                                                                                                                                        

  Martinez et al, 2013[@b30-copd-9-469]       1,224                24                              FF/VI (100--200/25 μg qd)\     62                         72                                   44                                             Yes                                             Yes   Yes   Yes       Yes       Yes
                                                                                                   FF (100--200 μg qd)\                                                                                                                                                                                                          
                                                                                                   VI (25 μg qd)\                                                                                                                                                                                                                
                                                                                                   PLB qd                                                                                                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Postbronchodilator;

less than 12 hours LTOT was allowed.

**Abbreviations:** BDP, beclomethasone dipropionate; bid, twice a day; BUD, budesonide; FEV~1~, forced expiratory volume in I second; FF, fluticasone furoate; FM, formoterol; FP, fluticasone propionate; ITT, intention to treat; LTOT, long-term oxygen therapy; MF, mometasone furoate; NR, not reported; PLB, placebo; qd, once a day; SAL, salmeterol; VI, vilanterol.
